- In 2022, Pfizer formed a strategic agreement with Acuitas Therapeutics to incorporate a lipid nanoparticle (LNP) delivery system in the development of mRNA-based vaccines, including COMIRNATY (tozinameran), and other mRNA therapeutics. This innovation supports the growth of the active pharmaceutical ingredient (API) market by driving demand for high-quality, complex APIs used in advanced therapeutic modalities
- In 2022, Sanofi and IGM Biosciences entered into a strategic collaboration to advance the development and commercialization of IgM antibody agonists targeting oncology, immunology, and inflammatory diseases. The alliance contributes to the expansion of the active pharmaceutical ingredient (API) pipeline by driving innovation in complex biologic therapies
- In 2021, the U.S. Food and Drug Administration (FDA) approved a new long-acting injectable treatment for schizophrenia, developed jointly by Teva Pharmaceuticals and MEDinCell. The approval of this novel therapy increases demand for specialized active pharmaceutical ingredients (APIs) used in long-acting formulations, driving growth in the psychiatric segment of the API market
- In May 2024, Eli Lilly announced an expansion of its investment at its Lebanon, Indiana manufacturing facility, raising the total commitment to USD 9 billion. This expansion underscores the growing importance of advanced API manufacturing capabilities, particularly for peptide-based therapies. As global prevalence of obesity and diabetes continues to rise, such investments enhance supply chain resilience and production scalability—factors critical to sustaining growth in the global API market and addressing increasing therapeutic demand
- In April 2023, Eli Lilly announced an additional USD 1.6 billion investment in the construction of two new manufacturing facilities in Indiana, bringing its total investment in the state to USD 3.7 billion. These large-scale investments reinforce the growing need for robust and localized active pharmaceutical ingredient (API) manufacturing capabilities. By expanding production capacity for high-demand therapies across multiple therapeutic areas, Eli Lilly’s continued investment enhances supply chain security, supports the scaling of complex APIs, and contributes significantly to the growth and resilience of the global API market
